Phase 1 Study of Oral MG001

Conditions

• Safety and Tolerability in Healthy Subjects

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Accepted

Interventions

• mitragynine — DRUG
  Mu opioid receptor partial agonist
• Placebo — DRUG
  Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.

Study Details

This research study is the first time the new medication MG001 is being tested in people. MG001 is a formulation of mitragynine, a compound that comes from a plant called Mitragyna speciosa (sometimes known as kratom), which some people use on their own to help manage symptoms of opioid withdrawal. The purpose of this study is to understand how safe MG001 is, how well it is tolerated, and how the body processes it. About 32 healthy adult volunteers, both men and women, will take part. Before joining, participants will undergo screening tests up to four weeks in advance to make sure they are eligible and healthy enough. On the day before dosing, participants will be admitted to the clinic for final health checks, and those who qualify will be randomly assigned-by chance, like flipping a coin-to receive either a single dose of MG001 or a placebo (an inactive substance). Neither the participants nor the staff giving the medicine will know which one is given. The study drug will be administered after at least 10 hours of fasting, and participants will then remain in the research clinic under close medical observation for three nights, until Day 4. During this time, doctors and nurses will monitor participants' health, look for any side effects, and collect blood samples to see how MG001 moves through the body. A follow-up clinic visit on Day 7 will provide one last check-in and blood test. This design helps researchers gather important first information on the safety and tolerability of MG001, while protecting the health and well-being of participants.

Key Dates

Start date

Feb 28, 2026

Status verified

Sep 2025

Primary completion

Aug 31, 2026

Completion

Aug 31, 2026

Study Design

Enrollment

32 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: 25 mg dose
  oral administration in fasted state
• Experimental: 50 mg dose
  oral administration in fasted state
• Experimental: 75 mg dose
  oral administration in fasted state
• Experimental: 100 mg dose
  oral administration in fasted state
• Placebo Comparator: Placebo
  oral administration in fasted state

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events in Healthy Adult Participants [ Time Frame: 4 days in clinic, follow-up on day 7 ]

Central Contacts

• Debra Kelsh, MD
  913-696-1601
  [email protected]
• Sage Hannan, BA
  913-696-1601
  [email protected]

Locations (1)

Find similar trials in Overland Park, KS